UPDATE: Canaccord Genuity Starts Medivation (MDVN) at Hold
Get Alerts MDVN Hot Sheet
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Canaccord Genuity initiated coverage on Medivation (NASDAQ: MDVN) with a Hold rating and a price target of $60.00.
Analyst John Newman said, "We are initiating coverage on Medivation with a HOLD rating and $60 price target. We see 3Q14 approval for Xtandi in the pre-chemotherapy setting causing a urologist-driven inflection in growth."
"We estimate $2.9B in US peak sales for Xtandi by 2023. We see Xtandi use in earlier lines of prostate cancer treatment, driven by positive data and Urologist use, providing long-term growth. We model ~45,000 chemo-naïve, castration-resistant patients, 37% Xtandi market share, and ~$160,000 treatment costs in 2023 driving $2.7B in revenues, plus, ~2,200 chemo-refractory patients driving additional revenue of ~$200M."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $58.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- Acrivon Therapeutics Inc (ACRV) PT Lowered to $22 at Jones Trading
- Tyler Tech (TYL) PT Raised to $500 at Oppenheimer
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!